Acute Effects of DC7-2, a Meat Derived Octapeptide, on Appetite
Acute Effects of DC7-2, a Meat Derived Octapeptide, on Appetite
A double-blind, randomized crossover design with four arms including three experimental
 conditions and placebo will be applied. After having successfully completed screening
 procedures, eligible participants will be invited to four separate test days. The test days
 are separated with at least 7 days, however 4 days can be accepted for logistical reasons.
 During the entire course of the study, participants must remain weight stable and not change
 their diet or physical activity level. Significant changes in diet, physical activity level
 (evaluated by the sub-investigator) or weight change ±3 kg over the course of the study (from
 screening to completion of the last test day) results in exclusion of that subject.
For standardization, participants will be asked avoid excessive alcohol consumption (not
 above 1 unit and no alcohol at all from 8 pm the night before the test days) and intense
 physical activity 48 hours prior to the test day. Also, they will be asked to consume a
 standardized meal at home no later than 8 pm the night before the test days. This meal is
 prepared and delivered by the department.

 Furthermore, the participants must arrive at the study facilities in the morning after an
 overnight fast (from 10 pm) using non strenuous means of transportation.

 Over the course of the study (from screening (visit 1) to completion of the last test day
 (visit 5)), participants are not allowed to change body weight (±3 kg), diet or physical
 activity level (as judged by the sub-investigator). The participants will be weighed and
 asked about compliance with additional standardization before initiating each test day.
 Possible in-compliance with the standardization will be judged by the sub-investigator
 whether to result in rescheduling of the visit or to be recorded as a protocol deviation.

 Participants arrive at the study facility in the morning. Compliance with standardization is
 controlled along with registration of possible adverse events and use of concomitant
 medications. During the test days, participants are settled together with other participants,
 but separated at individual tables. During the meals, participants are settled into
 individual feeding cubicles, where they cannot see each other and are instructed not to talk
 to each other. Visual analogue scales (VAS') will be completed for measurement of fasting
 subjective appetite levels.

 The test products (capsules) will be provided prior to a standardized fixed breakfast, prior
 to a standardized fixed mid-morning snack and prior to an ad libitum meal. Immediately before
 and after each episode of capsules and food consumption and at 30 minutes intervals, VAS'
 will be completed. Energy intake will be calculated from the ad libitum meal.
Inclusion Criteria:

 -  Healthy men

 -  Age between 18 and 65 years

 -  BMI between 27-35 kg/m2

 Exclusion Criteria:

 -  Vegetarians

 -  Participants unable to consume or known to get nausea from consuming capsules

 -  Participants not able to comply with the study protocol, including consumption of the
 specific study foods (pictures of study foods shown at screening)

 -  Any known food allergies or food intolerance likely to affect the present study

 -  Weight change of ±3 kg two months prior to the study

 -  Vigorous physical activity more than 5 hours/week

 -  Alcohol intake above the recommendations from the Danish Health and Medicines
 Authority (>14 units/week)

 -  Substance abuse

 -  Smoking, smoking cessation within the past 3 months or nicotine use (electronic
 cigarettes, gum etc.). Irregular smokers accepted

 -  Use currently or within the previous 3 months of any medication or supplements known
 to affect appetite or body weight as judged by the investigators

 -  Chronic diseases (e.g. cancer, thyroid disease, heart disease, diabetes, neurological
 disorders, or sleep disorders) or other relevant health problems as judged by the
 investigators

 -  Simultaneous or within the past month participation in other clinical studies

 -  Participant's general condition contraindicates participating in the study, as judged
 by the investigators or the medical expert